Table 1.

Clinical trials of pazopanib in patients with renal cell carcinoma.

Study	Dose	Setting	No. of pts with mRCC	MSKCC risk category37,38 (F/I/P/U§)	Prior nephrectomy	Clear cell
Phase I23	50 mg and 100 mg three times weekly 50 to 2,000 mg once daily 300 mg and 400 mg twice daily.	Dose escalation	12/63	NR	NR	NR
Phase II34	800 mg once daily versus placebo	First-line, cytokine-naïve	225	43/41/2/14%	91%	Yes†
Phase III36	800 mg once daily versus placebo	First-line, pre- or post- cytokine	290*	39/55/3/3%*	89%*	Yes†

Notes:

^*Pazopanib arm only;

^†Clear cell or predominantly clear cell histology required.

Abbreviations: ^§F/I/P/U, favorable, intermediate, poor, or unknown risk status; NR, not reported.